Immune mediated colitis caused by lung cancer treatment with atezolizumab
Santiago González Vázquez 1 , Susana de la Riva Onandía 2 , José Ignacio Echeveste 3 , Miguel Muñoz Navas 4
Atezolizumab is an IgG1 isotype monoclonal antibody against the protein programmed cell death-ligand 1 (PD- L1). PD-L1 may be highly expressed in some tumors and is believed to inhibit immune cells that recognize and attack tumor cells. Inhibition of PD-L1 can remove its inhibitory effect and provoke an anti-tumor response.
In October 2016, the Food and Drugs Administration (FDA) approved atezolizumab for the treatment of patients with metastatic non-small cell lung cancer after disease progression during or following platinum based chemotherapy.
We present the case of a 43-year-old male with stage IV lung adenocarcinoma in progression, despite standard chemotherapy.